RESUMEN
Adamantinoma of the long bones and Ewing's sarcoma are two malignant tumours between which, at first sight, there seems to be no morphological and clinical relationship. Both tumours, however, are known to express cytokeratins. Adamantinoma is a tumour of true epithelial nature, predominantly expressing cytokeratins 14 and 19. Ewing's sarcoma, believed to be from neuroectodermal origin, like other mesenchymal tumours, can aberrantly express cytokeratin 8 and 18. In the literature there are some reports of tumours showing clinical and/or morphological overlap between adamantinoma and Ewing's sarcoma, suggesting a possible relationship. These studies are mostly based on the epithelioid configuration of these lesions and their cytokeratin expression on immunohistochemistry. This raises the question of whether there is occasionally a morphological similarity between adamantinoma and Ewing's sarcoma, or whether there is a common genetic background. The Ewing's sarcoma/primitive peripheral neuroectodermal tumour (PNET) family is characterized in 90-95% of cases by a t(11; 22) and in 5-10% of cases by t(21; 22). In the few reports in the literature on cytogenetic investigations on adamantinoma, these translocations were never found using classical karyotyping. This study investigated the putative presence of t(11; 22) and t(21; 22) in 14 cases of adamantinoma by RT-PCR. These translocations were not found in any of these cases. The results support the view that these tumours are genetically and clinically distinct, but may eventually show overlapping morphological and immunohistochemical features.
Asunto(s)
Ameloblastoma/genética , Neoplasias Óseas/genética , Sarcoma de Ewing/genética , Translocación Genética , Ameloblastoma/clasificación , Neoplasias Óseas/clasificación , Cromosomas Humanos Par 11 , Cromosomas Humanos Par 21 , Cromosomas Humanos Par 22 , Humanos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sarcoma de Ewing/clasificaciónRESUMEN
PURPOSE: Patients with invasive breast cancer may develop a local recurrence (LR) after breast-conserving therapy (BCT). Younger age has been found to be an independent risk factor for LR. Within a group of premenopausal node-negative breast cancer patients, we studied risk factors for LR and the effect of perioperative chemotherapy (PeCT) on LR. PATIENTS AND METHODS: The European Organization for Research and Treatment of Cancer (EORTC) conducted a randomized trial (EORTC 10854) to compare surgery followed by one course of PeCT (fluorouracil, doxorubicin, and cyclophosphamide) with surgery alone. From patients treated on this trial, we selected premenopausal patients with node-negative breast cancer who were treated with BCT to examine whether histologic characteristics and the expression of various proteins (estrogen receptor, progesterone receptor, p53, Ki-67, bcl-2, CD31, c-erbB-2/neu) are risk factors for subsequent LR. Also, the effect of one course of PeCT on the LR risk (LRR) was studied. RESULTS: Using multivariate analysis, age younger than 43 years (relative risk [RR], 2.75; 95% confidence interval [CI], 1.46 to 5.18; P =.002), multifocal growth (RR, 3.34; 95% CI, 1.27 to 8.77; P =.014), and elevated levels of p53 (RR, 2. 14; 95% CI, 1.13 to 4.05; P =.02) were associated with higher LRR. Also, PeCT was found to reduce LRR by more than 50% (RR, 0.47; 95% CI, 0.25 to 0.86; P =.02). Patients younger than 43 years who received PeCT achieved similar LR rates as those of patients younger than 43 years who were treated with BCT alone. CONCLUSION: In premenopausal node-negative patients, age younger than 43 years is the most important risk factor for LR after BCT; this risk is greatly reduced by one course of PeCT. The main reason for administering systemic adjuvant treatment is to improve overall survival. The important reduction of LR after BCT is an additional reason for considering systemic treatment in young node-negative patients with breast cancer.
Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Mastectomía Segmentaria , Recurrencia Local de Neoplasia/prevención & control , Adulto , Neoplasias de la Mama/cirugía , Terapia Combinada , Europa (Continente) , Femenino , Humanos , Persona de Mediana Edad , Análisis Multivariante , Atención Perioperativa , Premenopausia , Pronóstico , Factores de Riesgo , Resultado del TratamientoRESUMEN
PURPOSE: Many studies have focused on histological risk factors for local recurrence (LR) after breast-conserving therapy (BCT). In addition to histological factors, we studied alterations in the expression of various proteins in relation to LR using a case-control approach. METHODS AND MATERIALS: Ninety-nine LR occurred in a patient cohort of 1,481 tumors treated with BCT. These patients were randomly matched, each with two controls. Matching was performed for age group (< or = 50 and > 50 years), pN stage, and follow-up time. Histology slides were reviewed. Immunohistochemical staining was performed for the following proteins: bcl-2, CD31, cyclin D1, E-cadherin, EGF receptor, ER, PR, Ki-67, c-erbB2/neu, and p53. Statistical analyses were performed using conditional logistic regression. RESULTS: Sixty-six cases and 139 controls with invasive carcinoma remained for analysis. The following variables were significant risk factors for LR: young age (p = 0.006), high nuclear grade (p = 0.04), high mitotic count (p = 0.03), extensive DCIS around the tumor (p = 0.02) but not within the tumor, poorly differentiated type of DCIS (p = 0.03), > 20% ki-67 positive cells (p = 0.006), and PR negativity (p = 0.03). When the analysis was performed for patients < or = and > 50 years, these risk factors were found in the older patients, but not in the younger patients. CONCLUSION: High mitotic count and Ki-67 positivity are risk factors for LR. EDCIS surrounding the invasive tumor is a risk factor for LR, especially when of poorly differentiated type. Age is an important risk factor for LR independent of other risk factors, including alterations in oncogene expression.
Asunto(s)
Neoplasias de la Mama/patología , Carcinoma in Situ/patología , Carcinoma Ductal de Mama/patología , Proteínas de Neoplasias/metabolismo , Recurrencia Local de Neoplasia , Adulto , Distribución por Edad , Anciano , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/cirugía , Carcinoma in Situ/metabolismo , Carcinoma in Situ/cirugía , Carcinoma Ductal de Mama/metabolismo , Carcinoma Ductal de Mama/cirugía , Estudios de Casos y Controles , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Mastectomía Segmentaria , Persona de Mediana Edad , Proteínas de Neoplasias/genética , Estadificación de Neoplasias , Análisis de Regresión , Factores de RiesgoRESUMEN
OBJECTIVES: The presence of an eosinophilic infiltrate in patients with cervical squamous carcinoma has been shown to correlate with a worse overall survival, suggesting a less effective immune response in these cases. Since type 2 cytokines such as IL-4 and IL-5 are known to attract eosinophilic granulocytes, an immunohistochemical study was performed to gain further insight as to whether a type 1 or type 2 immune response is involved in eliciting an eosinophilic infiltrate. MATERIAL AND METHODS: Frozen tissue sections of 9 normal cervical tissues, 23 premalignant cervical lesions, and 23 cervical squamous carcinomas were stained by immunohistochemistry with monoclonal antibodies directed against IFN-gamma and IL-4 as representatives of a type 1 or a type 2 response, respectively. RESULTS: Normal tissues and premalignant lesions of the cervix did not contain eosinophilic granulocytes and showed very few IL-4- and IFN-gamma-positive cells. In cervical carcinoma the presence of IL-4 on tumor infiltrating cells correlated with the presence of eosinophilic granulocytes in the tumor (P value <0.01) and stroma (P value <0.05). IFN-gamma-positive cells did not show any such correlation. In addition, colocalization was observed of CD3- and IL-4-positive T lymphocytes indicating that IL-4 production is mediated by T lymphocytes. CONCLUSION: The relative increase of IL-4-positive cells in the presence of an eosinophilic infiltrate might thus reflect an imbalance between a type 1 and type 2 response, in favor of the latter. Since a type 1 response stimulates an adequate cellular response which is negatively regulated by type 2 cytokines, these findings might explain the worse clinical outcome seen in cervical cancer patients with an eosinophilic tumor infiltrate. These results may have implications when developing immunotherapeutical strategies for cervical cancer.